Systemic Sclerosis (Scleroderma): Epidemiology Forecasting Intelligence
Report ID: 228353 | Mar 2019 | No. of Pages: 70
|
Publisher's "Systemic Sclerosis (Scleroderma)-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Systemic Sclerosis (Scleroderma) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.
Our epidemiology services include:
- Incidence and prevalence
- Diagnosis rate, treatment rate and mortality patterns
- Epidemiology-based forecasting and disease trends
- Size of different patient segments in a disease area
- Population based: disease occurrence, co-morbidities and treatment patterns
- Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
- Patient treatment journey
- Treatment algorithm and guidelines
- Assesses the disease risk and burden
- Highlights the unmet needs
- Market driver and barrier
- Growth opportunities and market trend analysis
Methodology
- This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
- To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
- All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Our epidemiology services include:
- Incidence and prevalence
- Diagnosis rate, treatment rate and mortality patterns
- Epidemiology-based forecasting and disease trends
- Size of different patient segments in a disease area
- Population based: disease occurrence, co-morbidities and treatment patterns
- Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
- Patient treatment journey
- Treatment algorithm and guidelines
- Assesses the disease risk and burden
- Highlights the unmet needs
- Market driver and barrier
- Growth opportunities and market trend analysis
Methodology
- This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
- To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
- All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
TABLE OF CONTENTS1. Report Introduction
2. Systemic Sclerosis (Scleroderma) Epidemiology Overview at a Glance
3. Market Share Distribution of Systemic Sclerosis (Scleroderma)
4. Disease Background and Overview: Systemic Sclerosis (Scleroderma)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Systemic Sclerosis (Scleroderma) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Systemic Sclerosis (Scleroderma) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
7.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
7.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
7.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
7.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.1.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.1.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.1.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.1.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.2.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.2.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.2.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.2.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.3.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.3.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.3.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.3.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.4.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.4.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.4.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.4.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.5.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.5.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.5.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.5.6. Treated Cases of Systemic Sclerosis (Scleroderma)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
9.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
9.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
9.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
9.6. Treated Cases of Systemic Sclerosis (Scleroderma)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About Publisher
- Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Table 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Table 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Table 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Table 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Table 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Table 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Table 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Table 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Table 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France
Table 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Table 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Table 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Table 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Table 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Table 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Table 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Table 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Table 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Figure 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Figure 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Figure 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Figure 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Figure 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Figure 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in United France
Figure 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Figure 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Figure 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Figure 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Figure 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Figure 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Figure 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Figure 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Figure 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Indication Specific
2. Systemic Sclerosis (Scleroderma) Epidemiology Overview at a Glance
3. Market Share Distribution of Systemic Sclerosis (Scleroderma)
4. Disease Background and Overview: Systemic Sclerosis (Scleroderma)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Systemic Sclerosis (Scleroderma) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Systemic Sclerosis (Scleroderma) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
7.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
7.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
7.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
7.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.1.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.1.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.1.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.1.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.2.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.2.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.2.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.2.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.3.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.3.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.3.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.3.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.4.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.4.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.4.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.4.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
8.5.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
8.5.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
8.5.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
8.5.6. Treated Cases of Systemic Sclerosis (Scleroderma)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
9.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)-
9.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)-
9.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
9.6. Treated Cases of Systemic Sclerosis (Scleroderma)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About Publisher
- Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Table 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Table 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Table 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Table 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Table 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Table 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Table 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Table 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Table 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France
Table 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Table 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Table 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Table 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Table 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Table 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Table 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Table 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Table 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Figure 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States-
Figure 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Figure 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany-
Figure 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Figure 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France-
Figure 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in United France
Figure 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Figure 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy-
Figure 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Figure 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain-
Figure 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Figure 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK-
Figure 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Figure 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan-
Figure 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan
- Indication Specific
1. This report provides in depth analysis for changing competitive dynamics and keeps you ahead of competitors
2. It provides a forward looking perspective on different factors driving or restraining market growth
3. It provides a ten-year forecast assessed on the basis of how the market is expected to grow
4. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of various market segments
Connect With Us
+1-707-633-0404
sales@search4research.com
Related reports
|
|
ECG Management Systems Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Adult Day Care Services Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Virtual Microscopy Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Teledentistry Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Medical Second Opinion Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |